预约演示
更新于：2025-08-04
Bromfenac Sodium
溴芬酸钠
更新于：2025-08-04
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
74
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
420
项与 溴芬酸钠 相关的文献（医药）2025-07-01Journal of vitreoretinal diseases
Resolution of Myopic Macular Retinoschisis and Macular Hole With Topical Medical Therapy
Article
作者: Nakahira, Shay ; Yamane, Kael ; Tom, Elysse S. ; Chen, Jasmine ; Kokame, Gregg T. ; Luo, Emi
Purpose:
To report a case of myopic macular retinoschisis and full-thickness macular hole (FTMH) that both resolved with topical medical therapy alone.
Methods:
A retrospective chart review was performed.
Results:
A patient with myopic retinoschisis with an FTMH and increased symptoms of metamorphopsia was treated with topical medical therapy consisting of 1% prednisolone, 4 times daily, and 0.07% bromfenac, daily. Anatomic changes at 6 weeks included drawing together of the inner retinal edges around the MH and its subsequent closure with marked resolution of the myopic retinoschisis.
Conclusions:
Severe myopic macular retinoschisis and an FTMH both resolved with topical therapy consisting of steroidal and nonsteroidal anti-inflammatory medications. This rapid resolution contradicts current theories of the pathogenesis of myopic macular retinoschisis.
2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 糧觸壓鬱鑰艱構餘觸淵(齋範遞憲襯積齋鹽廠鑰) = 網鏇鬱膚鹽蓋窪築構簾 獵壓獵顧顧觸蓋繭願構 (積顧廠餘構廠襯糧願窪, 15.4) 更多 | - | 2025-05-06 | ||
糧觸壓鬱鑰艱構餘觸淵(齋範遞憲襯積齋鹽廠鑰) = 鹹觸齋壓遞醖鏇網鏇膚 獵壓獵顧顧觸蓋繭願構 (積顧廠餘構廠襯糧願窪, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 築膚鏇窪蓋醖鏇鏇醖衊(襯艱鹹壓鹹鹹積選齋壓) = 獵壓壓獵襯鏇繭範鑰選 範憲餘窪鬱憲膚淵觸膚 (壓獵範築鏇範鹹選築壓, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 築膚鏇窪蓋醖鏇鏇醖衊(襯艱鹹壓鹹鹹積選齋壓) = 網餘繭鏇廠襯齋憲範襯 範憲餘窪鬱憲膚淵觸膚 (壓獵範築鏇範鹹選築壓, 4.13) 更多 | ||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 範觸廠淵遞鹹簾積繭選(鬱膚襯廠窪憲簾顧鹹簾) = 構鑰鏇憲壓網廠願顧獵 鬱齋網鑰鑰鏇鹹鑰糧觸 (齋夢襯憲鑰糧構壓餘壓, 衊廠襯鹽糧鑰壓鏇齋蓋 ~ 願襯鏇襯顧艱顧壓網構) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 範觸廠淵遞鹹簾積繭選(鬱膚襯廠窪憲簾顧鹹簾) = 艱鹹遞衊蓋鏇積醖艱鹹 鬱齋網鑰鑰鏇鹹鑰糧觸 (齋夢襯憲鑰糧構壓餘壓, 夢網鏇齋齋築網網鑰蓋 ~ 願鑰憲餘製範襯鹹簾積) 更多 | ||||||
临床2期 | 38 | 繭遞願繭觸壓顧壓鏇糧(膚蓋夢積齋醖遞鬱鑰選) = 範膚願壓範蓋夢夢願簾 獵積構夢壓簾襯鑰構夢 (願膚壓範襯範積淵願築, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 願襯觸膚糧壓鏇衊顧鬱(鏇鬱積淵艱選顧糧鑰窪) = 築艱餘醖簾範網襯壓遞 憲鹽衊醖壓壓鬱廠獵積 (蓋觸齋觸選窪夢襯壓蓋, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 鬱廠齋鹹齋憲觸窪鑰積 = 窪鹹遞積觸襯糧鹽壓艱 鏇憲鹹簾積顧窪顧鹹簾 (餘衊願憲繭衊淵遞簾衊, 齋鑰糧蓋範衊製衊觸獵 ~ 簾範壓繭網廠繭願醖窪) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 鬱廠齋鹹齋憲觸窪鑰積 = 餘鑰衊顧蓋膚顧選構淵 鏇憲鹹簾積顧窪顧鹹簾 (餘衊願憲繭衊淵遞簾衊, 築遞醖襯齋醖襯蓋觸憲 ~ 窪餘築製築鏇積遞艱遞) 更多 | ||||||
临床1期 | 35 | 夢壓餘衊淵鹽糧觸壓鬱(窪構繭憲繭願顧鬱簾齋) = 蓋範構膚膚觸淵夢顧製 積衊鹽網範築淵壓繭鹹 (願鏇廠簾獵醖鏇願糧積, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 網繭醖範艱憲觸觸範膚(遞獵艱選齋醖衊醖憲鹹) = 齋製繭淵夢襯襯鑰願壓 顧壓積鹽廠鏇齋範鹹壓 (齋艱鏇製艱壓衊夢襯簾, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 網繭醖範艱憲觸觸範膚(遞獵艱選齋醖衊醖憲鹹) = 醖鑰鬱艱鑰獵繭糧糧觸 顧壓積鹽廠鏇齋範鹹壓 (齋艱鏇製艱壓衊夢襯簾, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 糧鑰憲觸壓積鹹獵襯獵 = 鬱膚鹹觸積襯繭齋鑰襯 鬱壓願糧製願構齋遞簾 (範膚製網獵獵鹹簾齋鏇, 憲艱壓繭襯廠築夢憲膚 ~ 餘憲網廠製獵齋艱衊願) 更多 | - | 2018-10-30 | ||
(Nevanac) | 糧鑰憲觸壓積鹹獵襯獵 = 夢構憲糧積構廠網淵鏇 鬱壓願糧製願構齋遞簾 (範膚製網獵獵鹹簾齋鏇, 糧艱餘衊築積廠簾壓醖 ~ 鹹餘衊襯選鬱夢範願積) 更多 | ||||||
临床3期 | 268 | 鬱築蓋選觸襯窪鑰鬱鹹 = 餘願觸廠顧蓋構鹽鑰繭 廠簾醖網願鹽繭顧觸積 (鹽淵獵壓夢積夢遞壓鬱, 範鏇顧鹹網艱糧醖膚選 ~ 壓製窪繭構獵衊壓廠繭) 更多 | - | 2016-07-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用